Japanese Safety and Efficacy Study of Enoxaparin in Patients With Hip Fracture Surgery

Sanofi54 enrolled

Overview

The purpose of this study is to evaluate the effects of enoxaparin on bleeding and venous blood clots in patients with hip fracture surgery.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Hip Fractures

Interventions

enoxaparin (XRP4563)DRUG

14 days of treatment

Eligibility

Sex: ALLMin age: 20 Years

Medical Language ↔ Plain English

Inclusion Criteria: * femoral neck inside or outside fracture Exclusion Criteria: * any major surgery on lower limbs within 3 months * clinical signs of deep vein thrombosis * use of non-steroidal anti-inflammatory drugs * severe hepatic disease or renal insufficiency

Locations (1)

Sanofi- Aventis Administrative Office

Tokyo, Japan

Outcomes

Primary Outcomes

bleeding events

Time frame: 28 days

Secondary Outcomes

incidence of venous thromboembolism

Time frame: 28 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.